139 related articles for article (PubMed ID: 37861450)
1. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study.
Oomen PGA; Dijkstra S; Hofstra LM; Nijhuis MM; Verbon A; Mudrikova T; Wensing AMJ; Hoepelman AIM; Van Welzen BJ
J Med Virol; 2023 Oct; 95(10):e29178. PubMed ID: 37861450
[TBL] [Abstract][Full Text] [Related]
2. Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy.
Dijkstra S; Hofstra LM; Mudrikova T; Wensing AMJ; Oomen PGA; Hoepelman AIM; van Welzen BJ
J Acquir Immune Defic Syndr; 2022 Apr; 89(5):575-582. PubMed ID: 34966148
[TBL] [Abstract][Full Text] [Related]
3. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
4. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
5. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Álvarez H; Mocroft A; Ryom L; Neesgaard B; Edwards S; Svedhem V; Günthard HF; Zangerle R; Smith C; Castagna A; d'Arminio Monforte A; Wit F; Stecher M; Lehman C; Mussini C; Fontas E; González E; Wasmuth JC; Sönnerborg A; De Wit S; Chkhartishvili N; Stephan C; Petoumenos K; Jaschinski N; Vannappagari V; Gallant J; Young L; Volny Anne A; Greenberg L; Martín-Iguacel R; Poveda E; Llibre JM;
Clin Infect Dis; 2023 Aug; 77(4):593-605. PubMed ID: 37052343
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
Martinez V; Marcelin AG; Morini JP; Deleuze J; Krivine A; Gorin I; Yerly S; Perrin L; Peytavin G; Calvez V; Dupin N
AIDS; 2005 Jul; 19(10):1065-9. PubMed ID: 15958838
[TBL] [Abstract][Full Text] [Related]
7. Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.
Darcis G; Maes N; Pasternak AO; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Elmoussaoui M; Fombellida K; Vaira D; Moutschen M
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818822
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J
HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664
[TBL] [Abstract][Full Text] [Related]
9. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
[TBL] [Abstract][Full Text] [Related]
10. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
[TBL] [Abstract][Full Text] [Related]
11. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
[TBL] [Abstract][Full Text] [Related]
12. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.
Hofstra LM; Mudrikova T; Stam AJ; Otto S; Tesselaar K; Nijhuis M; Wensing AM
PLoS One; 2014; 9(10):e110749. PubMed ID: 25354368
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.
Pasternak AO; Vroom J; Kootstra NA; Wit FW; de Bruin M; De Francesco D; Bakker M; Sabin CA; Winston A; Prins JM; Reiss P; Berkhout B;
Elife; 2021 Aug; 10():. PubMed ID: 34387543
[TBL] [Abstract][Full Text] [Related]
15. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
Elvstam O; Malmborn K; Elén S; Marrone G; García F; Zazzi M; Sönnerborg A; Böhm M; Seguin-Devaux C; Björkman P
Clin Infect Dis; 2023 Jan; 76(1):25-31. PubMed ID: 36100984
[TBL] [Abstract][Full Text] [Related]
16. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
Kleinmann WN; Pruszynski JE; Adhikari EH
Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
[TBL] [Abstract][Full Text] [Related]
17. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
[TBL] [Abstract][Full Text] [Related]
18. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
19. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
[TBL] [Abstract][Full Text] [Related]
20. Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.
Zoufaly A; Kiepe JG; Hertling S; Hüfner A; Degen O; Feldt T; Schmiedel S; Kurowski M; van Lunzen J
HIV Med; 2014 Sep; 15(8):449-57. PubMed ID: 24580846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
